ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non–small-cell lung cancer after complete surgical tumor resection remains under investigation. We present the rationale and study design for the ADAURA (ClinicalTrials.gov identifier, NCT02511106) trial, a multicenter, double-blind, randomized, placebo-controlled study. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2018.04.004

Authors: Yi-LongWu, Roy S. Herbst, Helen Mann, Yuri Rukazenkov, Marcelo Marotti and MasahiroTsuboi